Current possibilities and future perspectives for improving efficacy of allergen-specific sublingual immunotherapy
•SLIT is an efficient and non-invasive route for treatment of allergic disorders.•Adjuvants and delivery systems could enhance the efficacy of SLIT. Allergen-specific sublingual immunotherapy (SLIT), a safe and efficient route for treating type I hypersensitivity disorders, requires high doses of al...
Gespeichert in:
| Veröffentlicht in: | International immunopharmacology 2021-12, Vol.101 (Pt B), p.108350-108350, Article 108350 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 108350 |
|---|---|
| container_issue | Pt B |
| container_start_page | 108350 |
| container_title | International immunopharmacology |
| container_volume | 101 |
| creator | Sadeghi, Mahvash Keshavarz Shahbaz, Sanaz Dehnavi, Sajad Koushki, Khadijeh Sankian, Mojtaba |
| description | •SLIT is an efficient and non-invasive route for treatment of allergic disorders.•Adjuvants and delivery systems could enhance the efficacy of SLIT.
Allergen-specific sublingual immunotherapy (SLIT), a safe and efficient route for treating type I hypersensitivity disorders, requires high doses of allergens. SLIT is generally performed without adjuvants and delivery systems. Therefore, allergen formulation with appropriate presentation platforms results in improved allergen availability, targeting the immune cells, inducing regulatory immune responses, and enhancing immunotherapy's efficacy while decreasing the dose of the allergen. In this review, we discuss the adjuvants and delivery systems that have been applied as allergen-presentation platforms for SLIT. These adjuvants include TLRs ligands, 1α, 25-dihydroxy vitamin D3, galectin-9, probiotic and bacterial components that provoke allergen-specific helper type-1 T lymphocytes (TH1), and regulatory T cells (Tregs). Another approach is encapsulation or adsorption of the allergens into a particulate vector system to facilitate allergen capture by tolerogenic dendritic cells. Also, we proposed strategies to increasing the efficacy of SLIT via new immunopotentiators and carrier systems in the future. |
| doi_str_mv | 10.1016/j.intimp.2021.108350 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2598078603</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576921009863</els_id><sourcerecordid>2624985957</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-6a19b74990b56421844e738e27fa68afd5de7f5e1faadcd190af29dffc45a8ba3</originalsourceid><addsrcrecordid>eNp9kU-L1TAUxYMozj-_gUjAzWz6TNKkSTaCPMZRGHDjrEOa3ox5tGlNmgfv208eHV24cJVw-J17L-cg9J6SHSW0-3TYhbiGadkxwmiVVCvIK3RJlVQNlUS8rn_RyUbITl-gq5wPhFSd07foouVSMSbFJUr7khLEFS9zzqEPY1gDZGzjgH1ZSwK8QMoLuDUcq-7nhOvONB9DfMLgfXDWnfDssR1HSE8QmzMcqo5z6cdKFTtWy1TivP6CZJfTDXrj7Zjh3ct7jR6_3v3cf2seftx_3395aFyrydp0lupecq1JLzrOqOIcZKuASW87Zf0gBpBeAPXWDm6gmljP9OC948Kq3rbX6HabW8_9XSCvZgrZwTjaCHPJhgmtiFQdaSv68R_0MJcU63WGdYxrJbSQleIb5VINK4E3SwqTTSdDiTl3Yg5m68ScOzFbJ9X24WV46ScY_pr-lFCBzxsANY1jgGSyCxAdDCHV4M0wh_9veAbNk6KA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2624985957</pqid></control><display><type>article</type><title>Current possibilities and future perspectives for improving efficacy of allergen-specific sublingual immunotherapy</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Sadeghi, Mahvash ; Keshavarz Shahbaz, Sanaz ; Dehnavi, Sajad ; Koushki, Khadijeh ; Sankian, Mojtaba</creator><creatorcontrib>Sadeghi, Mahvash ; Keshavarz Shahbaz, Sanaz ; Dehnavi, Sajad ; Koushki, Khadijeh ; Sankian, Mojtaba</creatorcontrib><description>•SLIT is an efficient and non-invasive route for treatment of allergic disorders.•Adjuvants and delivery systems could enhance the efficacy of SLIT.
Allergen-specific sublingual immunotherapy (SLIT), a safe and efficient route for treating type I hypersensitivity disorders, requires high doses of allergens. SLIT is generally performed without adjuvants and delivery systems. Therefore, allergen formulation with appropriate presentation platforms results in improved allergen availability, targeting the immune cells, inducing regulatory immune responses, and enhancing immunotherapy's efficacy while decreasing the dose of the allergen. In this review, we discuss the adjuvants and delivery systems that have been applied as allergen-presentation platforms for SLIT. These adjuvants include TLRs ligands, 1α, 25-dihydroxy vitamin D3, galectin-9, probiotic and bacterial components that provoke allergen-specific helper type-1 T lymphocytes (TH1), and regulatory T cells (Tregs). Another approach is encapsulation or adsorption of the allergens into a particulate vector system to facilitate allergen capture by tolerogenic dendritic cells. Also, we proposed strategies to increasing the efficacy of SLIT via new immunopotentiators and carrier systems in the future.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2021.108350</identifier><identifier>PMID: 34782275</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adjuvant ; Adjuvants ; Adjuvants, Immunologic ; Allergen-specific immunotherapy ; Allergens ; Allergens - immunology ; Allergies ; Allergy ; Animals ; Antigen presentation ; Delivery system ; Dendritic cells ; Drug Delivery Systems ; Galectin-9 ; Humans ; Hypersensitivity ; Hypersensitivity - immunology ; Hypersensitivity - therapy ; Immune system ; Immune Tolerance ; Immunoregulation ; Immunotherapy ; Lymphocytes ; Lymphocytes T ; Oral administration ; Platforms ; Probiotics ; SLIT ; Sublingual Immunotherapy ; Sublingual Immunotherapy - methods ; T-Lymphocytes, Regulatory - immunology ; Vitamin D3</subject><ispartof>International immunopharmacology, 2021-12, Vol.101 (Pt B), p.108350-108350, Article 108350</ispartof><rights>2021 Elsevier B.V.</rights><rights>Copyright © 2021 Elsevier B.V. All rights reserved.</rights><rights>Copyright Elsevier BV Dec 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-6a19b74990b56421844e738e27fa68afd5de7f5e1faadcd190af29dffc45a8ba3</citedby><cites>FETCH-LOGICAL-c390t-6a19b74990b56421844e738e27fa68afd5de7f5e1faadcd190af29dffc45a8ba3</cites><orcidid>0000-0003-3187-2381</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.intimp.2021.108350$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34782275$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sadeghi, Mahvash</creatorcontrib><creatorcontrib>Keshavarz Shahbaz, Sanaz</creatorcontrib><creatorcontrib>Dehnavi, Sajad</creatorcontrib><creatorcontrib>Koushki, Khadijeh</creatorcontrib><creatorcontrib>Sankian, Mojtaba</creatorcontrib><title>Current possibilities and future perspectives for improving efficacy of allergen-specific sublingual immunotherapy</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>•SLIT is an efficient and non-invasive route for treatment of allergic disorders.•Adjuvants and delivery systems could enhance the efficacy of SLIT.
Allergen-specific sublingual immunotherapy (SLIT), a safe and efficient route for treating type I hypersensitivity disorders, requires high doses of allergens. SLIT is generally performed without adjuvants and delivery systems. Therefore, allergen formulation with appropriate presentation platforms results in improved allergen availability, targeting the immune cells, inducing regulatory immune responses, and enhancing immunotherapy's efficacy while decreasing the dose of the allergen. In this review, we discuss the adjuvants and delivery systems that have been applied as allergen-presentation platforms for SLIT. These adjuvants include TLRs ligands, 1α, 25-dihydroxy vitamin D3, galectin-9, probiotic and bacterial components that provoke allergen-specific helper type-1 T lymphocytes (TH1), and regulatory T cells (Tregs). Another approach is encapsulation or adsorption of the allergens into a particulate vector system to facilitate allergen capture by tolerogenic dendritic cells. Also, we proposed strategies to increasing the efficacy of SLIT via new immunopotentiators and carrier systems in the future.</description><subject>Adjuvant</subject><subject>Adjuvants</subject><subject>Adjuvants, Immunologic</subject><subject>Allergen-specific immunotherapy</subject><subject>Allergens</subject><subject>Allergens - immunology</subject><subject>Allergies</subject><subject>Allergy</subject><subject>Animals</subject><subject>Antigen presentation</subject><subject>Delivery system</subject><subject>Dendritic cells</subject><subject>Drug Delivery Systems</subject><subject>Galectin-9</subject><subject>Humans</subject><subject>Hypersensitivity</subject><subject>Hypersensitivity - immunology</subject><subject>Hypersensitivity - therapy</subject><subject>Immune system</subject><subject>Immune Tolerance</subject><subject>Immunoregulation</subject><subject>Immunotherapy</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Oral administration</subject><subject>Platforms</subject><subject>Probiotics</subject><subject>SLIT</subject><subject>Sublingual Immunotherapy</subject><subject>Sublingual Immunotherapy - methods</subject><subject>T-Lymphocytes, Regulatory - immunology</subject><subject>Vitamin D3</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU-L1TAUxYMozj-_gUjAzWz6TNKkSTaCPMZRGHDjrEOa3ox5tGlNmgfv208eHV24cJVw-J17L-cg9J6SHSW0-3TYhbiGadkxwmiVVCvIK3RJlVQNlUS8rn_RyUbITl-gq5wPhFSd07foouVSMSbFJUr7khLEFS9zzqEPY1gDZGzjgH1ZSwK8QMoLuDUcq-7nhOvONB9DfMLgfXDWnfDssR1HSE8QmzMcqo5z6cdKFTtWy1TivP6CZJfTDXrj7Zjh3ct7jR6_3v3cf2seftx_3395aFyrydp0lupecq1JLzrOqOIcZKuASW87Zf0gBpBeAPXWDm6gmljP9OC948Kq3rbX6HabW8_9XSCvZgrZwTjaCHPJhgmtiFQdaSv68R_0MJcU63WGdYxrJbSQleIb5VINK4E3SwqTTSdDiTl3Yg5m68ScOzFbJ9X24WV46ScY_pr-lFCBzxsANY1jgGSyCxAdDCHV4M0wh_9veAbNk6KA</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Sadeghi, Mahvash</creator><creator>Keshavarz Shahbaz, Sanaz</creator><creator>Dehnavi, Sajad</creator><creator>Koushki, Khadijeh</creator><creator>Sankian, Mojtaba</creator><general>Elsevier B.V</general><general>Elsevier BV</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3187-2381</orcidid></search><sort><creationdate>202112</creationdate><title>Current possibilities and future perspectives for improving efficacy of allergen-specific sublingual immunotherapy</title><author>Sadeghi, Mahvash ; Keshavarz Shahbaz, Sanaz ; Dehnavi, Sajad ; Koushki, Khadijeh ; Sankian, Mojtaba</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-6a19b74990b56421844e738e27fa68afd5de7f5e1faadcd190af29dffc45a8ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adjuvant</topic><topic>Adjuvants</topic><topic>Adjuvants, Immunologic</topic><topic>Allergen-specific immunotherapy</topic><topic>Allergens</topic><topic>Allergens - immunology</topic><topic>Allergies</topic><topic>Allergy</topic><topic>Animals</topic><topic>Antigen presentation</topic><topic>Delivery system</topic><topic>Dendritic cells</topic><topic>Drug Delivery Systems</topic><topic>Galectin-9</topic><topic>Humans</topic><topic>Hypersensitivity</topic><topic>Hypersensitivity - immunology</topic><topic>Hypersensitivity - therapy</topic><topic>Immune system</topic><topic>Immune Tolerance</topic><topic>Immunoregulation</topic><topic>Immunotherapy</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Oral administration</topic><topic>Platforms</topic><topic>Probiotics</topic><topic>SLIT</topic><topic>Sublingual Immunotherapy</topic><topic>Sublingual Immunotherapy - methods</topic><topic>T-Lymphocytes, Regulatory - immunology</topic><topic>Vitamin D3</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sadeghi, Mahvash</creatorcontrib><creatorcontrib>Keshavarz Shahbaz, Sanaz</creatorcontrib><creatorcontrib>Dehnavi, Sajad</creatorcontrib><creatorcontrib>Koushki, Khadijeh</creatorcontrib><creatorcontrib>Sankian, Mojtaba</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sadeghi, Mahvash</au><au>Keshavarz Shahbaz, Sanaz</au><au>Dehnavi, Sajad</au><au>Koushki, Khadijeh</au><au>Sankian, Mojtaba</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current possibilities and future perspectives for improving efficacy of allergen-specific sublingual immunotherapy</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2021-12</date><risdate>2021</risdate><volume>101</volume><issue>Pt B</issue><spage>108350</spage><epage>108350</epage><pages>108350-108350</pages><artnum>108350</artnum><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>•SLIT is an efficient and non-invasive route for treatment of allergic disorders.•Adjuvants and delivery systems could enhance the efficacy of SLIT.
Allergen-specific sublingual immunotherapy (SLIT), a safe and efficient route for treating type I hypersensitivity disorders, requires high doses of allergens. SLIT is generally performed without adjuvants and delivery systems. Therefore, allergen formulation with appropriate presentation platforms results in improved allergen availability, targeting the immune cells, inducing regulatory immune responses, and enhancing immunotherapy's efficacy while decreasing the dose of the allergen. In this review, we discuss the adjuvants and delivery systems that have been applied as allergen-presentation platforms for SLIT. These adjuvants include TLRs ligands, 1α, 25-dihydroxy vitamin D3, galectin-9, probiotic and bacterial components that provoke allergen-specific helper type-1 T lymphocytes (TH1), and regulatory T cells (Tregs). Another approach is encapsulation or adsorption of the allergens into a particulate vector system to facilitate allergen capture by tolerogenic dendritic cells. Also, we proposed strategies to increasing the efficacy of SLIT via new immunopotentiators and carrier systems in the future.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>34782275</pmid><doi>10.1016/j.intimp.2021.108350</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-3187-2381</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1567-5769 |
| ispartof | International immunopharmacology, 2021-12, Vol.101 (Pt B), p.108350-108350, Article 108350 |
| issn | 1567-5769 1878-1705 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2598078603 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adjuvant Adjuvants Adjuvants, Immunologic Allergen-specific immunotherapy Allergens Allergens - immunology Allergies Allergy Animals Antigen presentation Delivery system Dendritic cells Drug Delivery Systems Galectin-9 Humans Hypersensitivity Hypersensitivity - immunology Hypersensitivity - therapy Immune system Immune Tolerance Immunoregulation Immunotherapy Lymphocytes Lymphocytes T Oral administration Platforms Probiotics SLIT Sublingual Immunotherapy Sublingual Immunotherapy - methods T-Lymphocytes, Regulatory - immunology Vitamin D3 |
| title | Current possibilities and future perspectives for improving efficacy of allergen-specific sublingual immunotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T02%3A13%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20possibilities%20and%20future%20perspectives%20for%20improving%20efficacy%20of%20allergen-specific%20sublingual%20immunotherapy&rft.jtitle=International%20immunopharmacology&rft.au=Sadeghi,%20Mahvash&rft.date=2021-12&rft.volume=101&rft.issue=Pt%20B&rft.spage=108350&rft.epage=108350&rft.pages=108350-108350&rft.artnum=108350&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2021.108350&rft_dat=%3Cproquest_cross%3E2624985957%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2624985957&rft_id=info:pmid/34782275&rft_els_id=S1567576921009863&rfr_iscdi=true |